See more : Grade Upon Technology Corp (6739.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of SOPHiA GENETICS SA (SOPH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SOPHiA GENETICS SA, a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
You may be interested
- Aeria Inc. (3758.T) Income Statement Analysis – Financial Results
- Instructure Holdings, Inc. (INST) Income Statement Analysis – Financial Results
- Daiwa Computer Co., Ltd. (3816.T) Income Statement Analysis – Financial Results
- Toast, Inc. (TOST) Income Statement Analysis – Financial Results
- PGS Software S.A. (PSW.WA) Income Statement Analysis – Financial Results
SOPHiA GENETICS SA (SOPH)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.sophiagenetics.com
About SOPHiA GENETICS SA
SOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Saint-Sulpice, Switzerland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 62.37M | 47.56M | 40.45M | 28.40M | 25.36M |
| Cost of Revenue | 19.46M | 16.31M | 15.23M | 10.71M | 7.53M |
| Gross Profit | 42.91M | 31.25M | 25.22M | 17.69M | 17.83M |
| Gross Profit Ratio | 68.80% | 65.71% | 62.35% | 62.29% | 70.30% |
| Research & Development | 36.97M | 35.37M | 26.58M | 18.59M | 15.02M |
| General & Administrative | 53.30M | 55.82M | 41.51M | 18.97M | 15.67M |
| Selling & Marketing | 28.42M | 28.27M | 28.74M | 17.43M | 19.41M |
| SG&A | 81.72M | 84.08M | 70.24M | 36.40M | 35.08M |
| Other Expenses | -954.00K | -377.00K | -108.00K | -129.00K | 16.00K |
| Operating Expenses | 117.74M | 119.08M | 96.71M | 54.86M | 50.12M |
| Cost & Expenses | 137.20M | 135.38M | 111.94M | 65.57M | 57.65M |
| Interest Income | 4.55M | 1.32M | 20.00K | 96.00K | 86.00K |
| Interest Expense | 588.00K | 639.00K | 658.00K | 840.00K | 976.00K |
| Depreciation & Amortization | 8.34M | 5.57M | 3.61M | 2.39M | 1.91M |
| EBITDA | -70.70M | -82.67M | -70.84M | -38.76M | -30.74M |
| EBITDA Ratio | -113.35% | -172.94% | -167.76% | -122.11% | -119.42% |
| Operating Income | -74.83M | -87.82M | -71.49M | -37.17M | -32.29M |
| Operating Income Ratio | -119.97% | -184.66% | -176.73% | -130.86% | -127.30% |
| Total Other Income/Expenses | -3.67M | 238.00K | -2.02M | -3.84M | -1.34M |
| Income Before Tax | -78.50M | -87.59M | -73.51M | -41.23M | -33.63M |
| Income Before Tax Ratio | -125.85% | -184.16% | -181.72% | -145.16% | -132.60% |
| Income Tax Expense | 486.00K | -136.00K | 168.00K | -1.89M | 162.00K |
| Net Income | -78.98M | -87.45M | -73.68M | -39.34M | -33.79M |
| Net Income Ratio | -126.63% | -183.87% | -182.14% | -138.52% | -133.23% |
| EPS | -1.22 | -1.36 | -1.15 | -0.62 | -0.53 |
| EPS Diluted | -1.22 | -1.36 | -1.15 | -0.62 | -0.53 |
| Weighted Avg Shares Out | 64.75M | 64.10M | 63.86M | 63.86M | 63.86M |
| Weighted Avg Shares Out (Dil) | 64.75M | 64.10M | 63.86M | 63.86M | 63.86M |
SOPHiA GENETICS Launches MSK-IMPACT® powered with SOPHiA DDM™ at AMP 2024
Launch of new application enables global access to highly recognized solid tumor profiling assay BOSTON and ROLLE, Switzerland , Nov. 21, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology leader in data-driven medicine, announced the global launch...
SOPHiA GENETICS SA (SOPH) Q3 2024 Earnings Call Transcript
SOPHiA GENETICS SA (NASDAQ:SOPH ) Q3 2024 Earnings Conference Call November 5, 2024 8:00 AM ET Company Participants Kellen Sanger - Head of Strategy and Investor Relations Jurgi Camblong - Co-Founder and Chief Executive Officer George Cardoza - Incoming Chief...
SOPHiA GENETICS Promotes Ross Muken to President and Appoints George Cardoza as Chief Financial Officer
BOSTON and ROLLE, Switzerland , Nov. 5, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today announced that Ross Muken, previously Chief Financial Officer ("CFO") and Chief Operating Officer ("COO"), has been...
SOPHiA GENETICS Reports Third Quarter 2024 Results
Clinical growth reaccelerates with record analysis volume; Cash burn improves 39% BOSTON and ROLLE, Switzerland , Nov. 5, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the...
SOPHiA GENETICS to Announce Financial Results for Third Quarter 2024 on November 5, 2024
BOSTON and ROLLE, Switzerland , Oct. 22, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the third quarter of fiscal year 2024 before...
SOPHiA GENETICS Presents Ground-Breaking Multimodal Research on AI-Driven Patient Stratification at ESMO 2024
Research highlights the use of multimodal machine learning to identify non-small cell lung cancer patients predicted to derive the most benefit from combination immunotherapy BOSTON and ROLLE, Switzerland , Sept. 14, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare...
SOPHiA GENETICS Announces Poster Presentations at ESMO 2024
Research presented will include the applications of new diagnostic tools and machine learning multimodal signatures in clinical trials BOSTON and ROLLE, Switzerland , Sept. 12, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global...
SOPHiA GENETICS Announces Updates on SOPHiA UNITY at ESMO 2024
The global collective intelligence network aims to accelerate precision oncology research and care BOSTON and ROLLE, Switzerland , Sept. 12, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced...
SOPHiA GENETICS and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy Testing
The companies commit to bring cutting-edge liquid biopsy testing to 20 institutions globally over the next 12 months BOSTON and ROLLE, Switzerland , Sept. 10, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global...
SOPHiA GENETICS Announces Validation of Novel Clinical Trial Assay Together with Precision for Medicine at World Clinical Biomarkers & CDx 2024
The companies share how their collaboration enables clinical trial enrollment for a novel cancer therapy for oncogene amplified cancers in development by Boundless Bio BOSTON and ROLLE, Switzerland , Sept. 5, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare...
Source: https://incomestatements.info
Category: Stock Reports